Mede­or’s cell ther­a­py boosts im­mune tol­er­ance in reg­is­tra­tional tri­al of donor kid­ney re­cip­i­ents

Mede­or Ther­a­peu­tics’ Phase III sin­gle-dose cell ther­a­py has seen more than half of a spe­cif­ic group of donor kid­ney re­cip­i­ents stop im­muno­sup­pres­sion ther­a­py for two …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER